In the second quarter, Finnish forest products company Stora Enso had a surprising loss in its Paper and Writing segment. Even though the secular headwinds for publishing paper in Europe are well known, Stora had previously been able to turn a consistent profit in the business in recent years. Management says it is stepping up its cost-cutting efforts in response to the loss, but many … Continue reading STERV Sees Loss in Paper and Writing Segment
Last week, Incyte Corporation (INCY) received a milestone payment of $60 million from Novartis (NVS) pertaining to the reimbursement of Jakavi in Europe. The drug has been approved by the European Commission to treat adults suffering from primary myelofibrosis (MF), post-polycythemia vera MF or post-essential thrombocythemia MF. It is a common practice of small pharma companies to enter into agreements with larger pharma companies for … Continue reading Biotech Stock Incyte Receives $60M Milestone Payment
Good news flowed in at Regeneron Pharmaceuticals (REGN) when the FDA cleared the company’s highly successful injectable eye drug for macular edema following retinal vein occlusion (RVO), a common retinal vascular disorder. Approval for the broad RVO indication includes sub-indications like, macular edema following branch retinal vein occlusion (BRVO) and macular edema following central retinal vein occlusion (CRVO). We remind investors that Eylea is already … Continue reading Biotech Stock News: Regeneron’s Eylea Gets An Important Approval From FDA
CF Industries reported second-quarter results that were generally in line with analysts’ expectations. Nitrogen volumes were up 2.2% year over year as the nitrogen application season in North America finished at a rapid pace following delays to planting caused by wet weather in the Corn Belt. Last season, warm weather in the spring pulled planting forward. For the first six months of 2013, nitrogen volumes … Continue reading CF Industries Continues to Boast Solid Earnings in Q2
Parker Hannifin delivered fourth-quarter earnings of $1.78 per diluted share, resulting in full-year earnings of $6.26 per share. Both metrics were below our expectations as sluggish global demand in Parker’s end markets continues to stunt revenue growth. Additionally, the company has struggled to keep margins flat, which amplifies the impact on earnings. For 2014, the firm will spend roughly $100 million on restructuring, which should … Continue reading Parker Hannifin Falls Short of Expectations in Fourth Quarter
Tourmaline Oil reported second-quarter results after the market closed on Friday. Despite weatherrelated setbacks, the company still increased production, and has now set the stage to deliver phenomenal growth in the second half of the year. Results for the quarter lined up with expectations. Production averaged 70.1 thousand barrels of oil equivalent per day versus our forecast of 70.9 mboe/d. Earnings per share was spot-on … Continue reading Tourmaline Posts Impressive Quarter Despite Challenges
